Diabetes mellitus and cardiovascular mortality across the spectrum of aortic stenosis.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
28 10 2022
Historique:
received: 25 01 2022
accepted: 15 05 2022
pubmed: 14 6 2022
medline: 2 11 2022
entrez: 13 6 2022
Statut: epublish

Résumé

Current data regarding the impact of diabetes mellitus (DM) on cardiovascular mortality in patients with aortic stenosis (AS) are restricted to severe AS or aortic valve replacement (AVR) trials. We aimed to investigate cardiovascular mortality according to DM across the entire spectrum of outpatients with AS. Between May 2016 and December 2017, patients with mild (peak aortic velocity=2.5-2.9 m/s), moderate (3-3.9 m/s) and severe (≥4 m/s) AS graded by echocardiography were included during outpatient cardiology visits in the Nord-Pas-de-Calais region in France and followed-up for modes of death between May 2018 and August 2020. Among 2703 patients, 820 (30.3%) had DM, mean age was 76±10.8 years with 46.6% of women and a relatively high prevalence of underlying cardiovascular diseases. There were 200 cardiovascular deaths prior to AVR during the 2.1 years (IQR 1.4-2.7) follow-up period. In adjusted analyses, DM was significantly associated with cardiovascular mortality (HR=1.40, 95% CI 1.04 to 1.89; p=0.029). In mild or moderate AS, the cardiovascular mortality of patients with diabetes was similar to that of patients without diabetes. In severe AS, DM was associated with higher cardiovascular mortality (HR=2.65, 95% CI 1.50 to 4.68; p=0.001). This was almost exclusively related to a higher risk of death from heart failure (HR=2.61, 95% CI 1.15 to 5.92; p=0.022) and sudden death (HR=3.33, 95% CI 1.28 to 8.67; p=0.014). The effect of DM on cardiovascular mortality varied across AS severity. Despite no association between DM and outcomes in patients with mild/moderate AS, DM was strongly associated with death from heart failure and sudden death in patients with severe AS.

Identifiants

pubmed: 35697496
pii: heartjnl-2022-320897
doi: 10.1136/heartjnl-2022-320897
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1815-1821

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Augustin Coisne (A)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille University Hospital Center, Lille, Hauts-de-France, France augustincoisne@hotmail.com.
Cardiovascular Research Foundation, New York, New York, USA.
Skirball Center for Innovation, Cardiovascular Research Foundation, New York, New York, USA.

David Montaigne (D)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille University Hospital Center, Lille, Hauts-de-France, France.

Sandro Ninni (S)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille University Hospital Center, Lille, Hauts-de-France, France.

Nicolas Lamblin (N)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur, Lille University Hospital Center, Lille, Hauts-de-France, France.

Gilles Lemesle (G)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur, Lille University Hospital Center, Lille, Hauts-de-France, France.

Pascal Delsart (P)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille University Hospital Center, Lille, Hauts-de-France, France.

Alexandre Filiot (A)

CHU Lille, INCLUDE: Integration Center of the Lille University Hospital for Data Exploration, Lille University Hospital Center, Lille, Hauts-de-France, France.

Paul Andrey (P)

CHU Lille, INCLUDE: Integration Center of the Lille University Hospital for Data Exploration, Lille University Hospital Center, Lille, Hauts-de-France, France.

Pierre Balaye (P)

Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de santé et des Pratiques médicales, F-59000, Lille University Hospital Center, Lille, Hauts-de-France, France.

Laura Butruille (L)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille University Hospital Center, Lille, Hauts-de-France, France.

Raphael Decoin (R)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille University Hospital Center, Lille, Hauts-de-France, France.

Eloise Woitrain (E)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille University Hospital Center, Lille, Hauts-de-France, France.

Juan F Granada (JF)

Cardiovascular Research Foundation, New York, New York, USA.
Skirball Center for Innovation, Cardiovascular Research Foundation, New York, New York, USA.

Bart Staels (B)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille University Hospital Center, Lille, Hauts-de-France, France.

Christophe Bauters (C)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur, Lille University Hospital Center, Lille, Hauts-de-France, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH